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5ABSTRACT
This thesis describes the induction of in vitro graft-versus- 
leukaemia (GVL) activity following bone marrow transplantation 
(BMT) for chronic myeloid leukaemia (CML).
BMT is currently the only curative therapy for patients with CML 
but its success is limited mainly by the immunologically mediated 
complication of graft-versus-host disease (GVHD) which accounts 
directly or indirectly for approximately 50% of all transplant 
related deaths. Attempts to reduce the incidence and severity of 
GVHD by depleting the donor marrow of T cells have been successful 
but have been associated with a high incidence of leukaemic 
relapse. This suggests that the donor marrow exerts an as yet 
poorly defined GVL effect which is abrogated by the removal of 
donor lymphocytes.
The work detailed in this thesis was designed to induce in vitro 
GVL activity that might be separable from GVHD in man, as this 
approach could lead to improvements in clinical transplantation. 
The experiments involved incubating donor and recipient lymphocytes 
with supraphysiological concentrations of cytokines, in particular 
interleukin-2 (IL-2), and assessing the activity of these effector 
cells in cytotoxic and clonogenic assays. In addition the origin 
and activity of the adherent lymphokine activated killer (ALAK) 
cells in patients who had relapsed following BMT was studied.
6The major conclusions to emerge from this work are:
1. Short term (18 hours) incubation of lymphocytes in alpha 
interferon enhances natural killer (NK) but not lymphokine 
activated killer (LAK) activity, whereas incubation with IL-2 
increases both NK and LAK killing. Neither cytokine was capable 
of inducing GVL activity following short term incubation.
2. Long term (7 days) incubation of lymphocytes in IL-2 resulted 
in significant GVL activity in over half of the patients who were 
tested. This GVL activity was mediated by cells with the phenotype 
of NK cells and resulted in the killing of autologous and 
allogeneic CML cells. The effector cells mediating this GVL 
activity were able to kill clonogenic CML cells with relative 
sparing of donor marrow progenitor cells.
3. The ALAK cells in patients who relapsed following BMT were of 
donor origin in most patients but one patient had recipient cells 
which were part of the Ph-positive clone. The ALAK cells derived 
from some of the patients demonstrated in vitro GVL activity.
As the effectors mediating this activity were activated NK cells 
and not T cells, GVL and GVHD may be separable in man. 
Administration of cytokines following T cell depleted BMT could 
therefore in theory reduce the risk of GVHD without at the same 
time increasing the risk of leukaemic relapse.
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CHAPTER 1
INTRODUCTION
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CHRONIC MYELOID LEUKAEMIA
In 1845 several authors described a disease of the spleen 
associated with suppuration of the blood1’3. This is the condition 
now known as chronic myeloid leukaemia (CML), a myeloproliferative 
disorder of clonal origin that arises from the malignant 
transformation of a single pluripotent haemopoietic stem cell4.
CML comprises about 20% of all cases of leukaemia with an annual 
incidence of 1 per 100,000 of the population. This incidence 
appears to be constant worldwide5. There is a slight male 
predominance (male:female ratio 1.4:1). The disease is seen in all 
age groups with a peak incidence in the fifth and sixth decades of 
life. Lack of concordance of CML in monozygotic twins suggests 
that CML is an acquired disorder, but in most cases there are no 
known predisposing factors. The incidence of CML was significantly 
increased in the survivors of the atomic bomb explosions at 
Hiroshima and Nagasaki who were exposed to high levels of 
radiation6'7, and in a group of patients given radiotherapy for 
ankylosing spondylitis8, but for most patients radiation plays no 
definite role in causation. There is no evidence that toxic 
chemicals or viruses are risk factors for CML. The majority of 
patients present with symptoms related to anaemia, splenomegaly or 
bleeding, but increasingly the diagnosis is made before the onset 
of symptoms - leukocytosis is recognised as the result of a routine 
blood test performed for totally unrelated reasons. The laboratory
17
findings are of a leukocytosis with a marked increase in 
myelocytes, neutrophils, eosinophils and basophils with a low 
neutrophil alkaline phosphatase score.
CML is usually a biphasic disease. After a median period of about 
three years the "benign" chronic phase evolves to a so-called 
blastic phase, sometimes preceded by a recognisable accelerated 
phase. This blastic or acute phase is the terminal stage of the 
disease, which is usually refractory to chemotherapy. Myeloblastic 
transformation has been notoriously difficult to treat, although 
return to chronic phase can be established after lymphoblastic 
crisis. The median duration of survival of untreated CML is 31 
months9.
PATHOGENESIS
There was little progress in the understanding of the pathogenesis 
of the disease until the discovery in 1960 that cells from the 
marrow of patients with CML were characterized by a deletion in the
long arm of one of the group G chromosomes - the Philadelphia (Ph)
10 • . . .  chromosome . This was therefore the first malignant disease to be
associated with a consistent chromosomal defect. Over a decade
later Rowley showed that this was not a deletion but a reciprocal
translocation between the long arms of chromosomes 9 and 22, now
usually designated t(9;22)(q34; qll)11.
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The majority (90%) of patients with CML have the Ph chromosome in 
all or almost all of their myeloid cells at the time of diagnosis. 
The position of the breakpoint on chromosome 9 is rather variable 
from patient to patient but the breakpoint on chromosome 22 is 
localised within a relatively short (5.8 kilobase) sequence of DNA 
that has been termed the breakpoint cluster region (BCR)12. A 
proto-oncogene, ABL, which bears homology with the transforming 
sequence of the Abelson strain of Moloney murine leukaemia virus, 
is normally located at the end of the long arm of chromosome 9. 
In CML the distal end of the long arm of chromosome 9, including 
the ABL oncogene, is translocated to chromosome 22 and the distal 
end of the long arm of chromosome 22, including a portion of the 
3' (telomeric) end of the BCR gene, is translocated to chromosome 
9; as a consequence a new hybrid gene consisting of the 5' end 
(centromeric) end of the BCR gene and the ABL oncogene is formed 
on the 22q- chromosome13. This hybrid gene is responsible for the 
production of a novel mRNA of 8.5 kb in length14 and this in turn 
is associated with the production of a unique ABL-related protein 
of relative molecular mass (MR) 210 (P210)15. Unlike its normal 
counterpart which has a MR of 145, the P210 has tyrosine kinase 
activity16, a function characteristic of the transforming sequences 
of other transforming retroviruses.
About 5% of patients have a disease that resembles CML but lacks 
the Ph chromosome. Some of these are clearly distinguishable from 
patients with Ph-positive disease on the basis of clinical features
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and the morphology of their blood and marrow; their prognosis is 
probably poorer than that of patients with Ph-positive disease17. 
Other patients with Ph-negative disease are indistinguishable on 
clinical and haematological grounds from those with Ph-positive 
disease; in some of these the BCR gene is involved in a genomic
rearrangement invisible at cytogenetic level but the same ABL-
• • • 18 •related P210 is produced as m  Ph-positive CML . The prognosis
for some of the patients in this group is the same as for patients
• • . • 19 20 • •with Ph-positive disease ' . Other patients sometimes erroneously 
diagnosed as CML have clinical features of chronic myelomonocytic 
leukaemia, an entity now included in the French-American-British 
classification of the myelodysplastic syndromes21.
TREATMENT
Radiotherapy was the first beneficial treatment of this disease and 
was reported by Pusey in 190222. Its value was reviewed 22 years 
later by Minot et al. and until the 1950s radiotherapy, either 
total body or splenic, was the mainstay of therapy9. Busulphan, 
introduced in 1953 by Galton23, and hydroxyurea, reported in 1966 
by Kennedy and Yarbro can alleviate symptoms in chronic phase 
disease but both agents are responsible for only a moderate 
increase in survival, but with no reduction in the percentage of 
marrow cells which are Ph-positive. The administration of alpha 
interferon (alFN) not only reduces the leukocytosis but may in some 
patients reduce the percentage of Ph-positive marrow cells,
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although this reduction was not usually sustained25. There have 
been several attempts to prolong survival with more intensive 
chemotherapy regimens. In general, life was not appreciably 
extended, but in a subgroup of patients in whom a reduction in the 
proportion of Ph-positive metaphases was seen survival was thought 
to be improved26.
In spite of the good control of symptoms with conventional 
cytotoxic drugs, the median duration of survival for patients aged 
less than 40 years is still only 4 years with almost all patients 
progressing to blast crisis and death27. This failure to alter the 
natural history of the disease has in the last 10 years encouraged 
study of the curative potential of high dose chemoradiotherapy 
followed by bone marrow transplantation (BMT).
BONE MARROW TRANSPLANTATION
The treatment of CML with cytotoxic agents is limited in part by 
their toxicity to host marrow. The availability of normal marrow 
for transplantation permits the administration of far higher and 
potentially curative doses of chemotherapy or chemoradiotherapy 
with reconstitution of the host's haemopoietic and immunological 
functions by the donor cells. In theory, therefore, ablation of 
the host marrow and transfusion of marrow from an human leukocyte 
antigen (HLA) identical donor could provide an opportunity for 
cure.
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Initial studies were performed on patients in blast crisis of 
disease who had an identical twin donor and were therefore not at 
risk of developing graft-versus-host disease (GVHD). Syngeneic BMT 
was performed with a variety of chemoradiotherapy regimens in 8 
patients who had entered blast crisis in the late 1970s28. The 
results of BMT in this late phase of the disease were generally 
poor; 3 patients died of leukaemia and 4 died of treatment 
complications. The eighth patient relapsed 10 months after BMT but 
was still in remission 4 years after a second syngeneic 
transplant29. The results of transplanting patients in blast crisis 
with allogeneic HLA-identical sibling donors were also 
disappointing30.
As the transformed cells were extremely resistant to intensive 
treatment, various investigators speculated that the best chance 
of cure was to offer patients with identical twins BMT while they 
were still in chronic phase. This led to studies of the value of
pO 71 7/
syngeneic BMT in chronic phase ' " . In the absence of GVHD the 
morbidity and mortality associated with the procedure were low but 
occasional patients died of "idiopathic" or cytomegalovirus- 
associated pneumonitis post-transplant. The probability of relapse 
after syngeneic transplantation seems rather variable. Based on 
experience obtained in Seattle28,31,32 and the Hammersmith Hospital 
in London34 the risk of relapse is no greater than that following 
HLA-identical sibling transplants for comparable patients. Others
22
have found that the risk is higher35.
The success of syngeneic BMT in chronic phase and the finding that 
patients with acute myeloid leukaemia in remission who received an 
allogeneic transplant while in good clinical condition had fewer 
transplant-related deaths and a far lower incidence of relapse than 
did patients transplanted in relapse36 encouraged physicians to 
offer allogeneic BMT to patients in chronic phase. A number of 
individual centres have now reported the results of transplant 
performed for CML in chronic phase using HLA identical sibling 
donors. The results of transplant in a relatively large series of 
patients have been reported by the International Bone Marrow 
Transplant Registry (IBMTR)37 and many of the patients in the 
individual reports are included in the IBMTR analyses. In summary 
the probability of survival and relapse at 4 years are 55% and 19% 
respectively37. It should be noted however that this recent IBMTR 
analysis included some patients who had received T cell depleted 
bone marrow grafts. If these are excluded from the analysis, the 
probability of relapse is 9% and the probability of leukaemia-free 
survival is 47%. These results agree relatively well with those 
of the large series reported independently from Seattle, in which 
the actuarial probabilities of survival and of relapse were 49% and 
2 0% respectively30.
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GRAFT-VERSUS-HOST DISEASE
Acute and chronic GVHD are among the principal causes of death in 
patients who receive transplants in chronic phase30. GVHD may lead 
directly to death or may contribute indirectly to death from other 
causes such as infection or interstitial pneumonitis. The survival 
of patients in chronic phase who develop grades II-IV acute GVHD 
is significantly worse than that of patients who do not37. 
Conversely in the recent IBMTR analysis of 405 CML patients 
allografted in chronic phase the probability of relapse was higher 
in those who did not develop chronic GVHD than in those who did, 
24% vs 12% (p < 0.004)37.
Most attempts to prevent GVHD have involved the use of 
immunosuppressive drugs given in the early post-transplant period. 
Methotrexate was initially used by the Seattle group starting 
within 24 hours of marrow transplantation and continuing for 
approximately 3 months38, but GVHD remained a serious problem 
affecting 25-60% of patients. More recently cyclosporin A has been 
used for prophylaxis of GVHD. Although initial uncontrolled 
studies suggested that it was more effective than methotrexate39, 
a controlled study in CML patients found no difference in the 
incidence of GVHD between patients given methotrexate and those 
given cyclosporin40. Because of these generally disappointing 
results, several attempts at combination therapy have been tried. 
No significant benefit was observed on combining methotrexate with
24
A1antithymocyte globulin when compared to methotrexate alone . More 
recently cyclosporin combined with methotrexate has resulted in a 
significantly lower incidence of GVHD than can be achieved by using 
either agent alone42. Nevertheless even with the best of the above 
regimens a significant number of patients die from GVHD or its 
sequelae. In an attempt to reduce the incidence and mortality of 
GVHD the focus was switched in the early 1980s to immunological 
techniques of prophylaxis and in particular the use of monoclonal 
antibodies to deplete the donor marrow of T cells.
T CELL DEPLETION OF DONOR MARROW
Various methods of depleting donor marrow of T cells have been 
used. The most common and convenient technique is to incubate 
donor marrow in vitro with anti-T lymphocyte monoclonal antibodies 
and complement to induce T cell lysis. The Royal Free Hospital 
group in London used monoclonals with CD6 and CD8 specificities43. 
The monoclonal used by the University of California at Los Angeles 
group has an anti-CD2 specificity44. Much experience worldwide has 
been accumulated with the use of Campath-1, an IgM monoclonal 
antibody which fixes human complement and is active against an 
incompletely defined antigen present on T and B lymphocytes, 
natural killer (NK) cells and on some monocytes45"47. Other 
techniques for the elimination of T cells include soybean lectin 
agglutination in conjunction with E-rosette formation and 
counterflow elutriation48,49. In general these different methods
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reduce the number of residual T cells in the marrow to <1% of the 
pretreatment levels.
The use of T cell depleted donor marrow is associated with a lower 
incidence and severity of GVHD, but the risk of graft failure is 
increased47. The graft failure may be due to survival in the host 
of chemoradioresistant immunologically competent cells which in the 
absence of T cells of donor origin are capable of mediating graft 
rejection50. The problem of graft failure has largely been overcome 
by increasing the intensity of the pretransplant conditioning 
regimen51.
In CML patients the major remaining problem associated with the use 
of T cell depleted bone marrow is a substantial increase in the 
risk of relapse which is seen with all the different methods of T 
cell depletion. This increased risk of relapse applies both to 
patients transplanted in chronic phase37 and to those transplanted 
in later phases. In a recent report from Seattle, 100% of patients 
transplanted in accelerated phase with T depleted marrow who 
survived long enough had evidence of recurrent leukaemia52; this 
contrasts with an actuarial risk of relapse of 55% for patients in 
acceleration transplanted with unmanipulated donor marrow53. One 
may conclude that depleting the donor marrow of T cells not only 
prevents GVHD but also abrogates a graft-versus-leukaemia (GVL) 
effect.
26
GRAFT-VERSUS-LEUKAEMIA ACTIVITY IN MAN
There is no totally satisfactory definition of GVL, but for 
operational purposes one might define GVL as any antileukaemic 
influence of the graft that is independent of the chemotherapy or 
chemoradiotherapy usually employed for cytoreduction and 
immunosuppression pre-transplant. If one accepts this definition 
then GVL probably plays a more important role in the cure of CML 
after BMT than in the acute leukaemias54. This conclusion derives 
in part from the observation that the actuarial relapse rate in 
patients who receive unmanipulated donor marrow is lower in CML 
transplanted in chronic phase than in acute myeloid leukaemia 
transplanted in first complete remission (10% versus 20%), whereas 
in transplants using T-depleted donor marrow cells, the reverse is 
true - the relapse rate is substantially higher in CML than in 
acute myeloid leukaemia (>60% versus 30%) 35,54,55.
More recently it has been shown that different methods of T cell 
depletion were associated with different frequencies of relapse. 
Use of antibodies reactive with T and NK cells or of broad 
specificity like Campath-1 increased the risk of relapse when 
compared to methods which only remove T cells from the donor 
marrow35. These data suggest that in some poorly defined manner 
preservation of NK cells in the donor marrow reduces the incidence 
of leukaemic relapse.
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Attempts have been made to quantify this in vivo GVL effect in man. 
Not surprisingly they have produced widely varying results. One 
report suggested that GVL activity may represent 50% - 150% of the 
magnitude of the anti-leukaemia effect of conditioning therapy56, 
while in another it was calculated to account for only the 
equivalent of a one-log cell kill57.
It is assumed that lymphocytes in the donor marrow are capable of 
mediating GVHD on one hand and a GVL effect on the other58. 
Clinical data are inconsistent with the notion that the only 
component of the transplant procedure critical for cure is the 
chemoradiotherapy and that the graft functions only as haemopoietic 
rescue. Instead it seems likely that T cells in the donor marrow 
contribute to cure by more than one mechanism59. Evidence is 
accumulating that the GVL effect in man has at least 3 components:
1. Antileukaemia activity associated with clinically evident 
GVHD60; 2. Antileukaemia activity that can operate in the absence 
of clinically overt GVHD but is mediated by allogeneic T cells35; 
and 3. Antileukaemia activity mediated by MHC unrestricted NK 
cells35.
EXPERIMENTAL GRAFT-VERSUS-LEUKAEMIA ACTIVITY
It could be argued that the increase in leukaemic relapse 
associated with T cell depletion should not have been unexpected 
and could have been predicted from research in animals. In animal
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model systems GVHD may exert an anti-leukaemic effect61. In animals 
at least some of the cells responsible for GVL reactions are 
clearly distinct from those causing GVHD61,62, but whether similar 
subpopulations are distinguishable in humans is currently unknown. 
However even in rodents it is not clear whether the same or 
different effector cells are responsible for the GVHD and the GVL 
effects63. In vivo GVL and GVHD reactivity are probably mediated 
by separate as well as overlapping populations61.
Of considerable interest is the recent demonstration that the 
administration of GVL specific T cell clones to leukaemic mice can 
cause a significant GVL effect without evidence of GVHD64. 
Cytotoxic activity does not appear to be the sole or most important 
functional property of cells contributing to GVHD, but cytotoxic 
T cells are important effectors of the GVL reaction. Lymphokine 
production or recruitment of other cells may be of equal or greater 
importance in GVHD. Currently our knowledge is incomplete. Some 
T cells found in autologous BMT recipients may even alter their 
functional activity in response to changing environmental 
conditions. In one study Class II antigen-specific T cells in 
murine autologous BMT hosts appeared to be nonlytic suppressor 
cells65; however a subsequent study revealed that these CD4+ T cells 
reverted to a lytic phenotype in the absence of interleukin-2 (IL- 
2)55.
If we cannot predictably modulate T cells to mediate a GVL effect,
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given the complexity of their interactions and regulation, we may 
be able to exploit their effector molecules and/or the lymphokines 
they produce through recombinant DNA technology. Lymphokine 
activated killer (LAK) cells offer an alternative and promising 
source of GVL effector cells.
BIOLOGICAL RESPONSE MODIFIERS
The concept of enlisting the immune system in the treatment of 
malignancy is not new. The recognition that the immune system was 
responsible for allograft rejection suggested that it might be 
possible to elicit immune-mediated tumour rejection. 
Administration of sublethal numbers of syngeneic tumour cells to 
a variety of experimental animals led to the development of cells 
capable of rejecting a challenge by an otherwise lethal inoculum 
of the same tumour cells66. Similarly, transfer of lymphoid cells 
from an animal challenged by the tumour to a syngeneic tumour- 
bearing host could result in tumour regression. Additionally, the 
possibility that the immune system was involved in the early 
elimination of spontaneous malignancies (immune surveillance) has 
been supported by previous work67.
The role of the immune system in controlling malignancies in man 
has been far more difficult to define. In 1969 Mathe et al. 
demonstrated that Bacillus Calmette Guerin (BCG) could prolong 
disease-free survival in childhood acute lymphoblastic leukaemia
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• • 68 following cytoreductive chemotherapy . When administered
intralesionally, BCG was shown to induce regressions of melanoma,
and when administered systemically, was reported to prolong disease
free survival in patients with resected malignant melanoma69,70.
Many anecdotal reports of the antitumour effects of BCG appeared,
but no controlled trials demonstrating significant antitumour
effects have been published71. Other nonspecific immunostimulants
(e.g. Corynebacterium parvum, levamisole) were evaluated, but the
limited number of responses at a time of rapid advances in the area
of chemotherapy led to a general loss of interest in this field72.
In the 1970s leukocyte interferon, and later recombinant alpha 
interferon (alFN), became available for laboratory and clinical 
evaluation73. Interferon was originally discovered in 1957 and 
described as a protein which "interfered" with viral growth74. It 
soon became apparent that there were several types of interferon 
and that they had many and varied biological properties. alFN is 
reported to have a direct antitumour effect and an indirect action 
by enhancing NK activity. Early reports of tumour regression in 
response to leukocyte interferon were not always substantiated, but 
renal cell carcinoma, melanoma, lymphoma, hairy cell leukaemia and 
CML were reported to respond to alFN25,75.
The availability of an effective recombinant immunomodulator 
rekindled interest in immunotherapy and generated the term 
"biological response modifiers" which was defined as "those agents
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or approaches that modify the host's biological response to tumour 
cells with resultant therapeutic effects"76. The cytokine which 
has proved to be of most interest in promoting antitumour activity 
in recent years is IL-2.
INTERLEUKIN-2
In 1965 Kasakura and Lowenstein and Gordon and MacLean 
independently demonstrated the release of a soluble mitogenic
• • 77 78 •factor m  mixed leukocyte cultures ' . It is conceivable that the
mitogenic activity observed was mainly due to the release of and
the response to the lymphokine, which is now called IL-2. This
molecule was "rediscovered" in 1976 and termed T cell growth factor
for its ability to sustain the continuous proliferation of T
lymphocytes79. In 1979, it was renamed as IL-2 by an international 
80committee . The IL-2 gene is located m  the midportion of the
81 •long arm of the human chromosome 4, at band q26-28 . It exists as
a single copy per haploid human genome, and is 5040 base pairs long 
and consists of 4 exons82.
IL-2 is the most important cytokine known so far to activate NK 
cells. This 15 kd glycoprotein produced by activated T helper 
cells is an inducer of proliferation and functional activity of T- 
cells, NK cells, macrophages and B cells83. To exert its biological 
effects IL-2 must interact with a specific membrane IL-2 receptor 
(IL-2R). However there was an apparent discrepancy until recently,
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since IL-2 responsive NK cells lacked the IL-2R Tac antigen (CD25), 
now known as the 55 kd alpha chain. Identification of the 75 kd 
IL-2R beta chain on NK cells has clarified this question and also 
contributed to the understanding of the requirements of high 
concentrations of IL-2 for NK activation84. The affinity of the 
alpha chain expressed on resting NK cells is about 100-fold less 
than that of the alpha/beta heterodimer high affinity IL-2R
• 85 • •expressed on activated T-cells . This has fuelled speculation that 
NK cells might serve as nonspecific auxiliary killer cells induced 
by immunocompetent T-cells at remote sites of activation with 
locally compartmentalised high concentrations of IL-2.
HUMAN CYTOTOXIC LYMPHOCYTES
Human cytotoxic lymphocytes can be divided into two major 
subgroups: (1) cytotoxic T cells (CTL) and (2) NK cells. Thymus
derived CTL are defined by the expression of a specific recognition 
structure - the T cell receptor (TCR) and by rearrangement of the 
T cell receptor alpha/beta chain or gamma/delta chain genes86. 
Functionally they are characterised by antigen-specific 
cytotoxicity that is generally restricted by the major 
histocompatibility complex (MHC) and can be blocked by 
anticlonotypic monoclonal antibodies87,88. The bone marrow derived 
NK population is less precisely characterized, though comprising 
about 10% of peripheral blood lymphocytes (PBL)89. The TCR genes 
are in germline configuration and CD3 expression is absent, while
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anti-CD56 and anti-CD16 monoclonal antibodies recognise these large
89-91 • • • •granular lymphocytes (LGL) . Their cytotoxic function is MHC 
unrestricted and directed against a broad range of target cells 
without prior sensitisation or activation92.
The characteristics of these two populations of cytotoxic effector 
cells, however, seemed to be inconsistent with experimental data 
from IL-2 activated lymphocytes. These cells were reported to 
exhibit a unique phenotype as well as a potent lytic activity 
against NK-resistant tumour targets. Therefore a separate lineage 
of cytotoxic lymphocytes was proposed, the LAK cell lineage93"95. 
LYMPHOKINE ACTIVATED KILLER CELLS
Subsequent examination of these findings demonstrated that known 
cell types accounted for this LAK activity. It is now apparent 
that the term LAK cell is a definition of function rather than 
phenotype. Culture of PBL in the presence of high concentrations 
of IL-2 favours proliferation of CD3- lymphocytes with broad killer 
activity, while at lower doses an expansion of highly antigen 
specific CD3+ T cells is observed96. A small subset of CTL are 
capable of mediating MHC unrestricted killing, these cells often 
coexpressing the CD3 and CD56 antigens, but most of the MHC 
unrestricted killing of IL-2 induced PBL is mediated by LAK cells 
with the phenotype of activated NK cells97.
The term LAK cells was introduced by Grimm and colleagues in
34
198293. They reported that PBL stimulated by IL-2 were able to
lyse autologous fresh tumour cells and a variety of tumour cell 
lines that were resistant to natural killer (NK) cell mediated
• • 98 • • •cytotoxicity . Subsequent experiments with adoptively transferred 
in vitro activated PBL in tumour-bearing mice supported the concept
• • • • • 99 •of antitumour activity m  vivo . Based on these experiments, 
studies in tumour patients with a combination therapy of high dose 
IL-2 and LAK cells were initiated in 1984100. Objective response 
rates of more than 25% in chemotherapy resistant tumours including
renal cell carcinoma and malignant melanoma were reported,
• • • • 101 • • • • encouraging further clinical trials . The initial enthusiasm was
blunted because of considerable toxicity of IL-2/LAK treatment and
short duration of most clinical responses in patients with advanced
solid tumours. One way of avoiding treatment failure might be to
use IL-2/LAK therapy in patients in good physical condition and
with a minimal residual tumour load. Patients in clinical
remission of disease following T cell depleted BMT for leukaemia
might be ideal candidates for such a treatment strategy.
MECHANISMS OF TARGET RECOGNITION AND KILLING
Several membrane molecules have been implicated in NK/LAK cell 
activation and function. By means of Fc receptor (CD16) expression 
NK cells are involved in antibody dependent cellular cytotoxicity. 
Capping of the Fc receptor induces mRNA and protein synthesis in 
NK cells as well as triggering the lytic mechanisms102. However
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soluble anti-CD16 monoclonal antibodies do not inhibit the killing
• * 1 0 3of the standard NK target K562, a CML-denved cell line 
Triggering of NK activity has also been achieved with monoclonal 
antibodies against lymphocyte function associated antigens LFA-1 
(CDlla/CD18 as alpha/beta subunits) and LFA-2 (CD2), suggesting 
that the intercellular adhesion molecule-1 (ICAM-1) and LFA-3 may 
be crucial target structures ' . Another member of the LFA
family, the complement receptor-3 (CR3) (CDllb/CD18 as alpha/beta 
subunit) is used by NK cells in complement mediated lysis via 
interaction with cell bound C3bi106. At the present time it appears 
that NK cells do not have a single predominant recognition receptor 
analogous to the TCR on T-cells. Rather they may interact with 
target cells using several surface molecules and their 
corresponding ligands. If this is correct one could speculate that 
lytic reactions could still develop even when a whole set of 
distinct receptor ligand systems is not available in a given 
effector-target cell interaction.
A crucial mediator of cytotoxic function is perforin as evidenced 
by experiments with anti-perforin monoclonal antibodies that block 
NK-dependent lysis of K562. Perforin is a homologue of the late 
complement components (C5-9), known as the membrane attack
107 • • • • . .complex . By assembling in a multimenc form, perforin binds to 
phosphorylcholine residues of the target cell membrane and induces 
pore-like membrane damage leading to osmotic cell lysis108.
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Additional components such as the cytokines tumour necrosis factor 
(TNF) or gamma interferon may also be involved in NK cell cytotoxic 
function109.
ROLE OF NK CELLS IN DEFENCE AGAINST LEUKAEMIA
Abnormally low NK activity is associated with an increased 
incidence of malignant disease, especially leukaemia. This is well 
evidenced by patients with Chediak-Higashi syndrome, X-linked 
lymphoproliterative or combined immune deficiency syndrome,
Sjogren's syndrome, and kidney allograft recipients with drug
. • • 110 • • • induced long term NK deficiency . It is possible that m  such
patients the increased incidence of leukaemia is secondary to a
primary defect in immune surveillance.
On the other hand, in previously healthy patients presenting with 
de novo acute leukaemia or CML the mechanism underlying the NK 
defect remains poorly characterised but there is evidence that the 
leukaemia itself may inhibit NK function. In patients with CML the 
NK cells are not part of the malignant Ph-positive clone111. At 
diagnosis patients with CML or acute leukaemia have deficient NK 
activity manifested by impaired tumour binding and lytic 
activity112. This defect in NK activity is, however, reversible by 
either incubating the NK cells in IL-2112 or by treating the acute 
leukaemia patients with chemotherapy and achieving a clinical 
remission113. In CML the blast cells have IL-2 receptors which are
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not present on their normal counterparts although IL-2 does not 
increase their proliferation114,115. Additionally patients with CML 
in chronic phase have increased circulating levels of soluble IL- 
2R; the levels rise further when the disease progresses to blast 
crisis115. The binding of IL-2 to its soluble IL-2R or CML blasts 
could provide a mechanism for "mopping up" circulating IL-2 and 
thereby preventing activation of the NK cells.
IMMUNE RECONSTITUTION FOLLOWING BMT
The recovery of a functional immune system following BMT is 
essential for the long term success of this treatment. The rate 
and degree of immunological recovery are influenced by a variety 
of factors including the type of GVHD prophylaxis and the severity
• • 116-119 • •and treatment of clinical GVHD . Selective or nonselective 
depletion of T-cells from the transplanted marrow may obviate the 
need for GVHD therapies which are immunosuppressive but may be 
associated with the removal of functionally mature cells from the 
marrow graft. Some studies have suggested that immune compromise 
may result from a slower rate of engraftment of myeloid and/or 
lymphoid cells as well as from removal of immunocompetent donor
derived cells transfused with the marrow graft in recipients of T
120-122  • • • • cell depleted grafts . Other studies m  murine and in human
systems have suggested that haemopoietic and immunological
reconstitution in recipients of T cell depleted marrow is not
impaired120,123,124. Treatment of bone marrow with monoclonal
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antibodies such as Campath-1 removes not only T cells but also 
functionally mature B cells and NK cells47'125,126, making it unlikely 
that either cellular or humoral donor immunity can be directly 
transferred with the marrow graft. The development of a donor 
derived immune system in recipients of marrow depleted of 
lymphocytes by this method therefore probably occurs from 
precursors of immunocompetent cells within the marrow graft.
NK cells are among the first lymphoid cells to recover after 
allogeneic BMT127,128. If the donor marrow has been depleted of T 
cells these regenerating cytotoxic cells are activated,
• • 129-131spontaneously producing IL-2, gamma interferon and TNF and
behaving like cells with LAK activity with the ability to kill MHC 
nonidentical virus-infected and malignant target cells not
• 127 132 133susceptible to NK cells ' ' . They respond to exogenous IL-2
with a further enhancement of cytokine production and a further
120 171 17Aincrease in cytotoxic effector function ' ' . The mechanisms by
which these cells are generated is not clear but it is known that 
they also appear after autologous BMT but not after chemotherapy
• • 135 • •for haematological malignancy ; therefore induction does not 
require either alloreactivity between donor and host or removal of 
T cells from the donor graft. The appearance of NK cells with LAK 
activity post-BMT probably reflects the immune dysregulation that 
follows immune reconstitution of the host, treated with ablative 
chemotherapy and total body irradiation, with an incomplete "immune 
network" derived initially only from cells present in the
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peripheral blood and marrow compartments. Immune regulation 
appears to be restored 3 to 4 months after BMT, since activation
• • 127 129 132of cytotoxic effector cells has by then disappeared ' ' .
In contrast, the reconstitution of the T cells and B cells occurs 
over a longer period of time. B cells first appear within 6 weeks 
of the transplant but immunoglobulin production does not reach 
normal levels until 7 to 9 months following conventional BMT and 
13 to 15 months following T cell depleted BMT119. The recovery of 
the T-cell populations is associated with a particularly low number 
of CD4+ helper cells in the first 6 months post-BMT, especially in
• • 119 126 •recipients of T cell depleted marrow ' . When this is coupled
with a high of normal number of CD8+ cells it results in CD4:CD8
• 128ratios that are below normal . It has been suggested that the
absolute deficiency of IL-2 producing CD4+ helper cells in T cell 
depleted BMT could result in immune dysregulation with loss of GVL 
activity with a resultant increase in leukaemic relapse55.
These findings have prompted some workers to consider enhancing the 
potential GVL effect with biological response modifiers such as IL-
2. It has been shown that IL-2 not only enhances LAK cell activity 
in vitro following BMT but also in vivo and that IL-2 infusions may 
be associated with secondary production of gamma interferon and TNF
• • • • • 136 137which may contribute to the antileukaemic activity ' .
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SCOPE OF THE THESIS
The above studies prompted me to consider methods of enhancing GVL 
activity following BMT for CML. The aims of the work were 
therefore:
1. to determine whether GVL activity was inducible in vitro?
2. to phenotype the effector cell populations;
3. to assess whether any identifiable GVL activity was directed 
towards committed nondividing myeloid cells or clonogenic leukaemic 
progenitor cells;
4. to compare the effects of the LAK cells on both normal marrow 
and leukaemic cells?
5. to try to separate GVL activity from GVHD; and
6. to determine the origin and activity of adherent LAK (ALAK) 
cells in patients who relapsed post-BMT.
All studies were performed in vitro using peripheral blood 
mononuclear cells (PBMC) from either the donors pretransplant or 
the recipients post-BMT. Chapter 2 describes the effect of short 
term exposure of recipients' PBMC to IL-2 and alFN and describes
their effect on NK and LAK activity as assessed in a chromium 
release assay system. Chapter 3 documents the NK, LAK and 
antileukaemic activity generated after 7 day incubation of the PBMC 
with IL-2 using a chromium release assay. In addition the 
phenotype of the effector cells, the contribution of the NK and T 
cell components to cytotoxic activity and the influence of pre- and 
post-BMT clinical parameters. Chapter 4 assesses the antileukemic 
activity of donor and recipient PBMC incubated with IL-2 for 7 days 
using a clonogenic assay. The influence of direct cell-cell 
contact and the differential killing of leukaemic and normal target 
cells is studied. In Chapter 5 I asked whether the ALAK cells of 
patients with CML who have relapsed post-BMT are of donor or 
recipient origin, whether they are part of the malignant clone and 
measure their antileukaemic activity in both cytotoxic and 
clonogenic assays.
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CHAPTER 2
INDUCTION OF IN VITRO LAK ACTIVITY FOLLOWING BONE MARROW 
TRANSPLANTATION FOR CHRONIC MYELOID LEUKAEMIA: USE OF 
SHORT TERM INCUBATION WITH INTERLEUKIN-2 AND ALPHA INTERFERON
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INTRODUCTION
The increased incidence of leukaemic relapse associated with T cell 
depletion of the donor marrow in allogeneic BMT recipients, 
initially reported in 198645, provided compelling evidence for the 
existence of a GVL effect in man. Although T cells were known to 
mediate GVL activity in these patients60, it was thought that the
• • • • 133NK population could also mediated antileukaemic effects 
Evidence from animals and man have demonstrated that NK cells can
• • 138directly kill tumour cells and tumour cell lines . NK cell 
function recovers rapidly after BMT and it has been suggested that 
augmentation of NK cell activity in the early post-transplant 
period with the recently available recombinant cytokines might 
provide a mechanism for enhancing GVL and therefore reducing the 
increase in leukaemic relapse associated with T cell 
depletion127,134. The cells responsible for this NK and LAK activity 
have been reported to be CD3- large granular lymphocytes97,112.
The cytokines that were thought to be of most interest in CML were 
alFN and IL-2. alFN is effective in controlling the white cell 
count in CML and unlike conventional chemotherapeutic agents may 
lead to a reduction or even to the disappearance of the Ph 
chromosome in the bone marrow metaphases of a proportion of 
patients25. Although much is known about the mechanism of action 
of alFN in experimental tumours the basis of its beneficial 
effects in CML have not been fully characterised. It has been
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reported that alFN can enhance in vitro NK activity following BMT140 
and a similar effect was also observed using in vitro IL-2132'134. 
It seemed reasonable to postulate that alFN- or IL-2-enhanced NK 
activity could be the basis of an in vitro GVL effect.
I therefore decided to investigate the in vitro effect of
recombinant alFN and IL-2 on the peripheral blood mononuclear cells 
of BMT recipients transplanted for CML using not only the standard 
cell lines but also the patients own pretransplant leukaemia as 
targets.
MATERIALS AND METHODS
STUDY POPULATION
Thirty-three patients were studied using IL-2 and 25 were studied 
using alFN. Patients gave informed consent to being studied
according to guidelines laid down by the Hammersmith Hospital
ethical committee. All were in complete haematological and 
cytogenetic remission following BMT for CML having received
allogeneic marrow from an HLA identical sibling donor. 
Pretransplant all patients were conditioned with cyclophosphamide 
(60 mg/kg/day x 2) and total body irradiation ( 6 x 2  Gy) . Some 
patients also received additional chemotherapy, total lymphoid 
irradiation or splenic irradiation. GVHD prophylaxis was with 
either T-cell depletion of the donor marrow with the rat monoclonal
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antibody Campath-1 or post-graft immunosuppression with cyclosporin 
with or without methotrexate. Patients were studied at intervals 
ranging from 4 weeks to 2 years post-BMT.
GENERATION OF CYTOKINE ACTIVATED CELLS
Peripheral blood was collected from the recipient following the 
transplant and PBMC were prepared by centrifugation on Lymphoprep 
(Nyegaard, Oslo). The low density cells were collected and washed 
twice with Ca2+, Mg2+ free Hanks1 balanced salt solution (HBSS) and 
resuspended in RPMI 1640 supplemented with 2 g/1 sodium
bicarbonate, 100 U/ml penicillin, 100 ug/ml streptomycin, 2 mmol/1 
L-glutamine and 10% heat-inactivated human AB serum (RPMI-AB).
For generation of cytokine activated cells, PBMC at a concentration 
of 1 - 2 x 106/ml were incubated for 18 hours in 5% C02 at 37 °C in 
RPMI-AB alone or in RPMI-AB containing either 500 U/ml recombinant 
IL 2 (kind gift of Cetus, Emeryville, CA) or 500 U/ml recombinant 
alFN 2a (kind gift of Roche, Welwyn Garden City, England). The 
cells were tested for cytotoxic activity after washing (see below) .
TARGET CELLS
Target cells were (1) the NK-sensitive cell line K562141, (2) an
NK-resistant LAK-sensitive Epstein-Barr virus transformed B 
lymphoblastoid cell line (LCL)142, (3) cryopreserved leukaemia cells
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from the transplant recipients. The cryopreserved CML cells were 
thawed for 1 minute at 37°C in a water bath, diluted in HBSS and 
centrifuged on Lymphoprep. The low density cells were then 
collected, washed twice in HBSS and resuspended in RPMI-AB. All 
cells were labelled by incubation with 250 uCi 51Cr (Na2Cr04) 
(Amersham, England) for 60 minutes. Following incubation the 
labelled cells were washed x3 in HBSS and resuspended in RPMI-AB.
CYTOTOXICITY ASSAY
• • • 127Details of these assays have been described previously . The 
target cell suspension at 5 x 104 cells/ml was dispensed in 100 ul 
volumes into U-shaped microtest plate wells. The effector cells 
were then added in a series of 5 different effector:target ratios, 
each in triplicate. The cells were incubated for 4 hours, after 
which half the supernatant was removed and 51Cr release quantitated 
on a LKB Wallac 1260 Multigamma counter (Wallac, Turku, Finland). 
The percentage specific lysis for each target was calculated as 
follows:
experimental release - spontaneous release
------------------------------------------- x 100%
maximum release - spontaneous release
where the maximum release was that obtained from target cells 
exposed to 1% Triton X-100 (New England Nuclear) and the 
spontaneous release was that observed when the target cells were
4/7
incubated in RPMI-AB . The spontaneous release was always less 
than 10% for the cell line targets and between 15 - 25% for the
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cryopreserved CML targets. Cytotoxic activity was considered 
positive when the value of experimental 51 Cr release was 
significantly above that of spontaneous 51Cr release according to 
the two-tailed Student's t-test.
RESULTS
IN VITRO RESPONSE TO alFN
In the 51Cr release assay effector cells from the 25 recipients 
always caused significant lysis of the NK-sensitive cell line K562. 
The data in Fig. 1 show the mean specific lysis + one standard 
error of K562 cells. Incubation of the effectors in alFN for 18 
hours increased cell lysis (p < 0.05) compared to control effectors 
in the absence of alFN. The addition of alFN did not however 
increase lysis of the NK-resistant LAK-sensitive LCL target (Fig. 
2) . In 8 separate assays alFN treated effectors failed to cause 
significant lysis of the recipients' leukaemia cells (data not 
shown).
IN VITRO RESPONSE TO IL-2
Effectors incubated in IL-2 always caused significant lysis of both 
the NK-sensitive K562 and the NK-resistant LCL cell lines. Culture 
of effectors in IL-2 caused a significant increase in the lysis of 
not only the K562 cells (Fig. 3) but also of the LCL cells (Fig.
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4) when compared to controls. Although both NK and LAK killing 
was enhanced with IL-2, the effector cells again failed to cause 
significant killing of recipient CML cells in 10 separate 
experiments (data not shown).
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Figure 1. Results from 25 patients whose effector cells were added 
to K562 cells at E:T ratios of 50, 25, 12, 6 and 3 to 1. Each E:T 
ratio was set up in triplicate and the points plotted are the mean + 
one standard error 51 Cr release. The graph shows dose-dependent 
killing of target cells with increased (p < 0.05) lytic activity 
seen in the effectors pretreated with alFN.
49
<0
'55
>
20 - i
alFN
control
10 -
ns
10 20  
Effector
30 40
LCL Ratio
50
Figure 2. Results from 25 patients whose effector cells were added 
to LCL cells at E:T ratios of 50, 25, 12, 6 and 3 to 1. Each E:T 
ratio was set up in triplicate and the points plotted are the mean + 
one standard error 51Cr release. The graph shows poor killing of 
target cells by both control effectors and in effectors pretreated 
with alFN.
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Figure 3. Results from 33 patients whose effector cells were added 
to K562 cells at E:T ratios of 50, 25, 12, 6 and 3 to 1. Each E:T 
ratio was set up in triplicate and the points plotted are the mean + 
one standard error 51Cr release. The graph shows dose-dependent 
killing of target cells with increased (p < 0.001) lytic activity 
seen in the effectors pretreated with IL-2.
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Figure 4. Results from 33 patients whose effector cells were added 
to LCL cells at E:T ratios of 50, 25, 12, 6 and 3 to 1. Each E:T 
ratio was set up in triplicate and the points plotted are the mean + 
one standard error 51Cr release. The graph shows dose-dependent 
killing of target cells with increased (p < 0.001) lytic activity 
seen in the effectors pretreated with IL-2 compared to poor lytic 
activity seen in the controls.
DISCUSSION
This study clearly indicates that although alFN can enhance NK 
activity in BMT recipients, it does not increase LAK or leukaemic 
cell killing (Figs. 1 and 2) . The results are in agreement with 
studies in hairy cell leukaemia, a disease highly responsive to in 
vivo alFN, where it was shown that alFN had no effect on LAK 
activity144. It is therefore unlikely that the administration of 
in vivo alFN to T cell depleted BMT recipients would reduce the 
incidence of leukaemic relapse by a direct cytotoxic effect by the 
NK cells on the CML cells. Where alFN has proved to be of clinical 
value post-BMT by reducing the percentage of Ph positive 
metaphases145'146, it is probable that it mediates this effect via a 
different mechanism. Although the precise nature of its action in 
vivo remains obscure, evidence is accumulating that alFN acts by 
inhibiting the proliferation of CML progenitors147. Recent studies 
have suggested that alFN selectively inhibits late progenitors, a 
compartment which is greatly enlarged in patients with CML148. In 
doing so, a comparable inhibition of normal and CML progenitors
• • I/O .will produce a greater absolute reduction of CML cells . With 
prolonged in vivo administration of alFN this effect could
• • • • 149encourage the restoration of normal Ph negative haematopoiesis 
However most studies using alFN in vitro have documented equivilant 
inhibition of both normal and leukaemic marrow progenitors and 
recent evidence has suggested that alFN may enhance the attachment 
of CML progenitors to marrow stromal elements and thereby bring the
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• 150CML cells under the normal bone marrow homeostatic mechanisms
Both NK and LAK activity are known to be increased following 
allogeneic BMT particularly in the first 3 months of immune
119 126 128 • •reconstitution ' ' . Studies performed with short term culture
of lymphocytes in IL-2 (Figs. 3 and 4) indicated that NK and LAK 
activity can be further enhanced even at longer intervals from 
transplant. These findings suggest that although NK and LAK 
activity is supranormal in BMT recipients their lymphocytes are not 
maximally stimulated. Some workers have suggested that this 
increased LAK activity, as defined by increased killing of NK- 
resistant LAK-sensitive cell line targets, might be associated with
• ♦ • • . • 127a direct antileukaemic effect in transplant recipients . The 
failure to cause significant lysis of the recipients1 pretransplant 
CML implies that no direct comparison can be made between LAK and 
antileukaemic activity.
In summary short term incubation of lymphocytes from allogeneic BMT 
recipients with recombinant cytokines in vitro can increase NK and 
LAK activity but does not generate effectors capable of killing the 
patients1 pretransplant CML cells. I therefore decided to study 
the effects of incubating the lymphocytes from transplant patients 
for a longer period (7 days) in IL-2 as this cytokine appeared to 
more efficacious than alFN. These studies are described in Chapter 
3.
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CHAPTER 3
INDUCTION OF IN VITRO LAK ACTIVITY FOLLOWING BONE MARROW 
TRANSPLANTATION FOR CHRONIC MYELOID LEUKAEMIAS USE OF 
7 DAY INCUBATION WITH INTERLEUKIN-2. CYTOTOXIC ASSAY.
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INTRODUCTION
The failure of short term incubation of lymphocytes in IL-2 to 
produce killing of the patients' pretransplant leukaemic cells 
prompted me to investigate the use of a longer in vitro incubation 
of the PBMC with IL-2. This decision was based not so much on the 
hope that longer exposure to IL-2 might empirically produce LAK 
cells with more potent antileukaemic activity but rather on the 
results of the preliminary clinical trials in solid tumours. These 
studies had used LAK cells which had been generated by exposing 
leukapheresed PBMC to high concentrations of IL-2 for 5 - 7  days 
and had demonstrated objective regression of some advanced 
metastatic malignancies, particularly melanomas and bladder
99-101carcinomas .
1 therefore designed studies to discover whether GVL activity could 
be induced in vitro following BMT for CML. As long term exposure 
to IL-2 could result in phenotypic changes in the effector cell 
population I set out to establish the phenotype of the effector 
cells. I wanted also to determine whether any such GVL effect was 
in theory separable from GVHD. I therefore undertook phenotypic 
and functional characterisation of IL-2 stimulated PBMC or LAK 
cells from recipients following BMT. This chapter describes an IL-
2 inducible in vitro GVL effect mediated by MHC unrestricted cells.
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MATERIALS AND METHODS
PATIENTS
Thirty-seven patients were studied in complete haematological and 
cytogenetic remission following BMT for CML. Twenty-six patients 
had received allogeneic marrow from HLA identical siblings, 7 
allogeneic marrow from HLA matched unrelated donors and 4 syngeneic 
marrow from identical twin donors. Pretransplant all patients were 
conditioned with cyclophosphamide (60 mg/kg/day x 2) and total body 
irradiation (6 x 2 Gy) . Some patients also received in vivo 
antilymphocyte monoclonal antibodies, additional chemotherapy, 
total lymphoid irradiation or splenic irradiation. GVHD 
prophylaxis consisted of T cell depletion of the donor marrow with 
the rat monoclonal antibody Campath-1 or post-graft 
immunosuppression with cyclosporin with or without methotrexate. 
Patients were studied at intervals ranging from 4 weeks to 10 years 
post-BMT. Each patient gave informed consent for these studies.
GENERATION OF LAK CELLS
Venous blood was collected from the recipient following the 
transplant and PBMC were prepared as described in Chapter 2. For 
generation of LAK cells, PBMC at a concentration of 1 - 2 x 106/rol 
were incubated for 7 days in 5% C02 at 37 °C in RPMI-AB containing 
500 U/ml recombinant IL-2. The cells were tested for cytotoxic
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activity after washing (see below).
ELIMINATION OF T LYMPHOCYTE SUBPOPULATIONS
Washed LAK cells were incubated for 60 minutes on ice with an anti- 
CD3 monoclonal antibody (UCHT1, kindly provided by Dr Peter
• • 151Beverley, ICRF, London) at saturating concentration . The cells 
were washed and centrifuged, resuspended and incubated with sheep 
anti-mouse IgG coated magnetic beads (Dynal, Oslo) on ice for 40 
min at a bead:cell ratio of 20:1. Following addition of 5 ml RPMI 
1640 the resuspended preparation was placed in a magnetic field for 
5 minutes. The cells in the supernatant were then withdrawn for 
use in the cytotoxicity assay.
SURFACE MARKER ANALYSIS
Phenotypic analysis was performed by indirect and two-colour direct
• ■ • 152immunofluorescence using standard techniques . Samples were 
analyzed on a Becton Dickinson FACScan flow cytometer. Monoclonal 
antibodies used were purchased from Becton Dickinson (Mountain 
View, CA) and were directed against CD3 (Leu 4), CD4 (Leu 3), CD8 
(Leu 2) , CD16 (Leu 11) and CD56 (Leu 19) antigens.
TARGET CELLS
Target cells were (1) the NK-sensitive cell line K562, (2) an NK-
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resistant LAK-sensitive Epstein-Barr virus transformed B 
lymphoblastoid cell line (LCL), and (3) cryopreserved leukaemia 
cells from the transplant recipients and from 37 different third 
party HLA-disparate patients with CML. Target cells were washed 
and labelled as described in Chapter 2.
CYTOTOXICITY ASSAY
Details of these assays have been described previously in Chapter 
2. The percentage specific lysis for each target was calculated 
as follows:
experimental release - spontaneous release
------------------------------------------- x 100%
maximum release - spontaneous release
Some results were expressed in lytic units defined as the number 
of effector cells/106 resulting in specific lysis of 60% of 5000
1 IlKtarget cells . The spontaneous release was always less than 10% 
for the cell line targets and between 15 - 25% for the
cryopreserved CML targets. Cytotoxic activity was considered 
positive when the value of experimental 51Cr release was 
significantly above that of spontaneous 51Cr release according to 
the Student's t-test.
In cold target competition studies, unlabelled allogeneic normal 
bone marrow cells or allogeneic CML cells were mixed with 51Cr 
labelled recipient CML cells at ratios of unlabelled (cold) to
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labelled (hot) ranging from 1:1 to 20:1 before addition to the 
microtiter plates. Effector cells were added at a constant E:T 
ratio (50:1) to the various cold:hot (C:H) combinations, and the 
percentage of specific lysis was determined in the cytotoxicity 
assay described above. Results were expressed as the percentage 
of specific lysis at the indicated C:H ratios.
STATISTICAL METHODS
Differences in cytotoxic activity or phenotypic analysis were 
analyzed using the two tailed Student's t-test.
RESULTS
SURFACE MARKERS
The phenotype of the effector LAK cells is shown in Table 1. The 
predominant phenotype of the LAK cell population was CD56+, CD8+, 
CD4-, with a variable number of CD3+ cells. The CD8+ fraction was 
usually split between the CD3+/CD8bnght and CD3-/CD8dlm populations, 
with the CD8dim cells coexpressing the CD56 antigen (Fig. 5) . 
Following culture in IL-2 there was an increase in the expression 
of the CD56 antigen concurrent with a reduction in the expression 
of the CD16 antigen (Fig. 6) with the CD56 population being either 
CD16- or CD16dim (Fig. 5) . Although we observed an increasing 
number of CD3+ T-cells and a reduced number of CD56+ natural killer
cells with time from transplant, these changes were not 
statistically significant. Furthermore, there was no significant 
difference in the phenotype of the effectors which were able to 
lyse the recipients' leukaemic cells and those which were not 
killers (Table 1).
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Figure 5. Flow cytometric analysis of day 7 LAK cells from a 
single patient. A. Histogram showing negative control staining 
with anti-mouse FITC and anti-mouse phycoerythrin (PE). B. 
Histogram showing: FLl FITC anti-CD3; FL2 PE anti-CD8. The
CD8bng t population coexpress the CD3 receptor whereas the CD8dim 
cells are largely CD3-. C. Histogram showing: FLl FITC anti-CD8; 
FL2 PE anti-Leul9 (CD56) . The CD8bnght cells are largely Leul9- 
whereas the CD8dim cells coexpress the Leul9 antigen. D. Histogram 
showing: FLl FITC anti-CD16; FL2 PE anti-Leul9 (CD56). The Leul9+ 
cells are either CD16- or CD16dim.
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■  Pre-IL2 incubation
H  Post-IL2 incubation
CD3 CD4 CD8 CD16 CD56
Figure 6. Surface marker analysis of peripheral blood mononuclear 
cells from 7 patients pre- and post-IL-2 incubation expressed as 
mean percentage + one standard deviation. Following culture with 
IL-2 I saw a reduced number of T cells with an increased number of 
NK cells though these differences were not significant. There was 
a reduction (p < 0.01) in the proportion of CD56 cells which 
coexpressed the CD16 antigen following IL-2 incubation.
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ACTIVITY OF EFFECTORS AGAINST CELL LINE TARGETS
The effectors generated after 7 days culture in IL-2 always caused 
significant lysis of the NK-sensitive cell line K562 and the NK- 
resistant LCL in 15 consecutive studies. However killing of the 
cell line targets did not predict killing of the patients' 
pretransplant leukaemia cells. Fig. 7 demonstrates the lytic 
activity against the NK-resistant LCL cell line targets of LAK 
cells from 7 patients where the effectors caused significant lysis 
of their pretransplant CML cells contrasted with the LAK cells from 
8 patients which did not kill recipient leukaemic cells. There was 
no significant difference in the cell line lytic potential between 
LAK cells which were or were not CML lytic indicating that CML 
cells appear to be more resistant to lysis than the cell line 
targets. Fig. 7 also shows the lytic activity against the 
recipient CML cells is significantly (p < 0.05) less than that 
against the LCL cell line.
65
8 -
n LCL (not CML lytic) 
♦ LCL (CML lytic)
+ Recipient CML
</> ■ ■■ 
c
3
O■ MM 
>%
6 -
IT 4 -
2 -
B
□
□
□
□
□
♦
♦
Targets
Figure 7. Lytic activity of LAK cells from 15 patients against the 
LCL cell line and recipient CML cells. All effectors resulted in 
significant (p < 0.05) lysis of the cell line target. The graph 
shows the LCL and CML lytic activity of 7 patients whose LAK cells 
demonstrated killing of their pretransplant leukaemic cells 
compared with 8 patients whose effectors failed to lyse their 
leukaemia. The data show no significant difference (p = 0.84) in 
the cell line lytic activity between those effectors which were or 
were not CML lytic indicating that failure to kill CML cells is due 
to target cell resistance to lysis. This point was reinforced when 
we compared the lytic activity against the LCL and CML targets in 
the 7 patients who showed significant lysis of the recipient 
leukaemia. Their LAK cells demonstrated significantly (p < 0.05) 
lower lytic activity for the CML cells.
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CYTOTOXICITY OF EFFECTORS AGAINST CML CELLS
In the 51Cr release assay LAK cells from 20 of 33 (61%) allogeneic 
and 2 of 4 syngeneic recipients killed recipient CML cells and in 
22 of 37 (59%) cases also killed the HLA disparate CML cells. The 
data in Fig. 8 show the mean specific lysis for the leukaemic 
targets in the 22 positive assays. In 9 cases (2 syngeneic) where 
I demonstrated killing of the recipients' CML cells, the effector 
cells were depleted of CD3+ T-cells and assessed for GVL activity 
in the same experiment. In all experiments the T-depleted 
effectors lysed the recipients' and the 3rd party CML cells with 
a slight though not significant increase in specific lysis when 
compared to the non-depleted LAK cells (Fig. 9).
LAK CELL EFFICACY VERSUS LEUKAEMIC CELL SUSCEPTIBILITY
I analyzed the data to look for variability in both the LAK cell 
lytic potential and the leukaemic target cell susceptibility to 
killing among the 37 patients (Table 2) . Patients were categorized 
into 4 groups. Patients in group 1 produced LAK cells with good 
lytic potential that killed more than one susceptible leukaemic 
target. Cells from patients in group 2 failed to lyse either 
target, but as these targets were not killed by effectors from any 
other patient, it cannot be determined whether this group 
represents poor effector lytic ability or resistant target cells. 
The LAK cells of the patients in group 3 were able to lyse 1 of the
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2 CML targets. The targets which were resistant to lysis were not 
susceptible to killing from other effectors used in separate 
experiments. This suggests a differential sensitivity of the 
leukaemic cells to lysis in different patients. The LAK cells from 
patients in group 4 were unable to kill at least one leukaemic 
target which had been susceptible to lysis when tested with 
effectors from other patients indicating that the LAK cells from 
group 4 patients were less active. These data suggest that both 
effector and target cell factors are important in determining the 
outcome of an assay.
COLD TARGET COMPETITION EXPERIMENTS
The results of 6 separate experiments using cold allogeneic normal 
bone marrow cells and cold allogeneic CML cells mixed with hot 
recipient CML cells are shown in Figures 10A and 10B. In 3 studies 
both types of cold target blocked the killing of the recipient CML. 
In 2 experiments killing was not blocked with either cold target 
and in 1 study killing was blocked with the cold CML cells but not 
with the normal bone marrow.
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Figure 8. Results from all patients whose LAK cells demonstrated 
significant lysis of the CML targets. LAK cells were added to 
recipient CML and allogeneic CML cells at E:T ratios of 50, 25, 12, 
6 and 3 to 1. Each E:T ratio was set up in triplicate and the 
points plotted are the mean + one standard error 51Cr release. The 
graph shows dose-dependent killing of both CML targets. There is 
no significant difference (p = 0.37) in the killing of the
recipients1 CML cells and the allogeneic CML cells according to the 
Student's t-test.
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T-replete LAK cells 
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Figure 9. Results from all 9 patients whose LAK cells were T cell 
depleted and who demonstrated significant lysis of the CML targets. 
Unmanipulated and CD3 depleted LAK cells were added to recipient 
CML and allogeneic CML cells at E:T ratios of 50, 25, 12, 6 and 3 
to 1. Each E:T ratio was set up in triplicate and the points 
plotted are the mean 51Cr release. The graph shows that T cell 
depletion of the effectors did not reduce their ability to lyse 
the leukaemic cells. There was no significant difference (p = 
0.42) in the killing of the recipients' and the allogeneic CML 
cells according to the Student's t-test.
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CORRELATION OF CLINICAL AND IN VITRO DATA
There was no correlation between the ability of the patients' LAK
cells to lyse their pretransplant cryopreserved CML cells and (a)
the interval from transplant to the time of assay? (b) whether the
donor marrow was T depleted or T replete and (c) the incidence and
severity of acute and chronic GVHD (Table 3) . None of the patients 
relapsed during the study period so we can make no comment about 
the relationship between in vitro GVL activity and the likelihood 
of relapse.
Table 3. Correlation of in vitro GVL activity with clinical 
parameters in 33 allograft recipients.
Clinical data GVL Detected GVL Absent
Patient no. 20 13
Median weeks from BMT to assay 65 58
T-cell depleted donor marrow 9 5
T-cell replete donor marrow 11 8
Acute GVHD: grades 0-1 15 9
grades II-IV 5 4
*Chronic GVHD: none 11 8
localised 5 3
generalised 3 2
* Only 32 patients were evaluable for chronic GVHD as one patient 
died within 3 months of the transplant.
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DISCUSSION
Adoptive immunotherapy with LAK cells and IL-2 is a new approach
• • • 99 100 •m  the treatment of malignant disease f . For haematological 
malignancies this strategy has been proposed for purging autologous 
bone marrow and as remission maintenance following conventional
153 , •chemotherapy or BMT . Although there is good evidence for the 
existence of enhanced natural killer and LAK cell activity 
following both autologous and allogeneic BMT, previous studies have 
in general used cell line targets rather than the recipient 
leukaemia cells127,132'134'135, and LAK cells have not been shown to 
mediate in vitro GVL activity.
In the early phase of immune reconstitution post-BMT CD3-, CD16+, 
CD56+ large granular lymphocytes with NK activity form up to 45% 
of the lymphocyte compartment and CD3+ cells are slow to
127 133 «reappear ' . Therefore one might have expected to generate LAK
cells with a predominantly NK phenotype from the patients studied 
during the first 3 months post-BMT. In practice LAK cells were 
generated with surface markers not usually present in significant 
numbers in the peripheral blood of normal individuals, i.e. 
CD8+dim/CD3-, CD8+dim/CD56+, CD56+/CD16- and CD5 6 +/CE>1 6 +dim, phenotypes 
which have been described following culture of lymphocytes in IL-
iq/ <|co
2 and in BMT recipients " . Although a greater percentage of
CD56+/CD3- cells was found in patients studied within 3 months of 
BMT there was no significant difference when compared to the LAK
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cell phenotype of patients studied at longer intervals from 
transplant. The inability to demonstrate phenotypic differences 
in the LAK cells which were or were not capable of mediating in 
vitro GVL activity could reflect the possibility that the GVL 
activity resides in a small subpopulation which I have not fully 
characterized. Alternatively it could reflect the variation in 
leukaemic target sensitivity which was seen in different patients 
(Table 2).
Conventionally LAK activity following BMT is tested using NK- 
resistant tumour cell line targets. Previous studies indicated 
that while fresh leukaemia cells are more resistant to killing by 
LAK cells than cell line targets there was a correlation between 
lysis of cell line targets and fresh leukaemic cells113,159. However 
my data indicate that LAK cells can in some cases kill substantial 
numbers of cell line target cells but induce no detectable lysis 
of the cryopreserved CML cells (Fig. 7). Thus correlating results 
using cell line targets and leukaemia cells is not always possible.
These experiments demonstrate that LAK cells generated from BMT 
recipients in remission whose lymphocytes are of donor origin133,134 
can kill recipient leukaemic cells in vitro in over half of the 
patients studied. This represents an inducible in vitro GVL 
effect. This effect was demonstrated in LAK cells from allograft 
recipients and also from 2 of the 4 syngeneic recipients. Although 
it is possible that killing of leukaemic cells following allogeneic
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BMT could be mediated by MHC-restricted T cells, I have shown GVL 
activity in the syngeneic setting even when the syngeneic LAK cells 
were T cell depleted indicating that the killing was probably 
mediated by MHC unrestricted effectors. The same mechanism might
• • 135operate m  the autograft setting . Furthermore although a subset 
of CD3+ cells is capable of MHC unrestricted killing97, depletion 
of CD3+ cells from the effector population obtained from the 
allograft recipients did not reduce the observed antileukemic 
activity (Fig. 9) , suggesting that the GVL activity was largely 
mediated by cells with the phenotype of CD3- natural killer cells. 
Additional evidence that this activity is MHC unrestricted comes 
from the observation that there was significant killing of 
allogeneic CML cells. Cold target competition studies failed to 
demonstrate a consistent pattern with both normal bone marrow cells 
and allogeneic CML cells capable of either blocking or not blocking 
the killing of the labelled recipient CML cells. When blocking 
occurred the effectors might have recognized receptors present on 
both leukaemic and normal cells; when there was a failure to block 
this could reflect a more resistant cold target cell. Results of 
these studies suggest that the LAK cells can recognize and interact 
with cell lines, leukaemic cells and normal bone marrow target 
cells.
Previous work in BMT recipients failed to show any correlation 
between LAK activity and the age of the patient, the speed of
• • • • 132 •engraftment or the incidence of infections . Our data also fail
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to demonstrate any association between the presence or absence of 
in vitro GVL activity and time from BMT to assay, GVHD prophylaxis 
or the presence of acute or chronic GVHD. It could be argued that 
the lack of correlation results from culturing PBMC in 
supraphysiological concentrations of IL-2 which produces cells with 
activities that have little in vivo relevance. On the other hand 
it is possible that in vivo this could provide a mechanism for 
enhancing MHC unrestricted GVL activity. As the CD3- LAK cells 
kill the leukaemic cells these effectors could in theory be 
exploited to reduce leukaemic relapse without the morbidity and 
mortality of GVHD.
Our results indicate a potential role for LAK cell therapy with or 
without in vivo IL-2 following BMT. In the context of syngeneic 
or autologous BMT, GVL activity could perhaps be generated without 
the risk of initiating or enhancing GVHD. In allogeneic BMT, 
however, the use of LAK cell therapy with in vivo IL-2 could 
promote the growth of donor alloreactive T cells with resultant 
GVHD. This might be avoided by depleting donor marrow of T cells
prior to the transplant or by depleting LAK cells generated in
• 160 vitro of CD3 positive cells
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CHAPTER 4
INDUCTION OF IN VITRO LAK ACTIVITY FOLLOWING BONE MARROW 
TRANSPLANTATION FOR CHRONIC MYELOID LEUKAEMIA: USE OF 
7 DAY INCUBATION WITH INTERLEUKIN-2. CFU-GM ASSAY.
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INTRODUCTION
In Chapter 3 I demonstrated that LAK cells could kill CML leukaemia 
cells in a cytotoxicity assay. A question not addressed was 
whether the leukaemic cells killed were clonogenic or committed 
cells with no proliferative potential. If IL-2/LAK therapy was to 
be of clinical value LAK cells would need to target and kill 
clonogenic leukaemic cells and also not compromise the function of 
normal bone marrow cells.
There are conflicting reports regarding the role of NK cells in
bone marrow graft rejection and the regulation of
• 161haematopoiesis . NK cells have been reported to have lytic
effects against normal bone marrow cells in vitro and in vivo via
direct cell-cell contact or via the production of lymphokines such 
as gamma interferon or tumour necrosis factor (TNF) 109»153'162-171 ^ 
Because LAK activity is primarily derived from IL-2 activated NK 
cells, LAK cells could theoretically harm normal haemopoietic 
progenitors cells. Therefore limitations to the use of IL-2/LAK 
therapy following BMT might be either due to failure of LAK cells 
to inhibit the growth of recipient leukaemia cells and/or toxicity 
of LAK cells towards the normal donor marrow cells.
To investigate these possible limitations we analyzed the effect 
of both donor and recipient LAK cells on the colony growth of both 
normal donor marrow and the recipient CML cells in a semisolid
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culture system. This Chapter describes an inducible GVL effect 
which inhibits the growth of clonogenic leukaemic cells with 
sparing of normal marrow progenitors.
MATERIALS AND METHODS
GENERATION OF LAK CELLS
Twenty-four patients were studied in complete haematological and 
cytogenetic remission following BMT for CML. Each patient gave 
consent for use of their blood in these studies. Fifteen patients 
had received allogeneic marrow from HLA identical siblings, 7 
allogeneic marrow from HLA matched unrelated donors and 2 syngeneic 
marrow from identical twin donors. Venous blood was obtained from 
the donors prior to the transplant and from the recipients 
following the transplant. PBMC were prepared as described in 
Chapter 2 and LAK cells were generated by a method identical to 
that described in Chapter 3.
TARGET CELLS
Target cells in these assays were cryopreserved CML mononuclear 
cells from the transplant recipients and cryopreserved donor marrow 
mononuclear cells. Recipient leukaemic cells were collected from 
the peripheral blood or bone marrow prior to the transplant. 
Normal human bone marrow was obtained after informed consent from
80
the donors at the time of the bone marrow harvest by aspiration 
from the posterior iliac crests. The target cells were collected 
in HBSS with 10 units/ml preservative-free heparin. The target 
cell suspension was diluted in HBSS and centrifuged over 
Lymphoprep. The light density cells were collected, washed twice 
in HBSS and resuspended in RPMI-AB and cryopreserved until used in 
the CFU-GM assay.
SURFACE MARKER ANALYSIS
Phenotypic analysis was performed using two-colour direct 
immunofluorescence as described in Chapter 3.
ASSAY FOR GRANULOCYTE-MACROPHAGE PROGENITOR CELLS (CFU-GM)
The target cells were thawed for 1 minute at 37°C in a water bath, 
diluted in HBSS followed by centrifugation on Lymphoprep. The low 
density cells were then collected, washed twice in HBSS and 
resuspended in RPMI-AB. 1 x 105 mononuclear cells in RPMI-AB 
either of normal donor marrow or recipient CML origin were pre­
incubated with or without the LAK cells at an effector:target ratio 
of 10:1 for 18 hours in liquid culture. After incubation the cells 
were resuspended and subsequently cultured in triplicate for CFU-
• • • 172GM in a methylcellulose culture system as described previously 
The methylcellulose based culture medium was prepared in bulk 
allowing the production of multiple identical 3.6 ml aliquots to
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which was added 0.4 ml (4 x 105) target cells + LAK cells. After 
mixing, 3 x 1 ml aliquots were decanted into sterile petri dishes 
and cultured at 37°C for 14 days. Each 1 ml aliquot contained 1% 
methylcellulose dissolved in 414 ul Iscove's modified Dulbecco's 
medium without supplements with L-glutamine (Gibco, Paisley, 
Scotland), 300 ul fetal calf serum (Sera-Lab, Sussex, England), 
100 ul fraction V bovine serum albumin (Sigma, Poole, England), 1 
ul 0.1M 2-mercaptoethanol (BDH, Poole, England), 10 ul 100 U/ml 
penicillin, 100 ug/ml streptomycin (Flow, Irvine, Scotland), 75 ul 
conditioned medium (culture supernatant from the 5637 bladder 
carcinoma cell line), and 100 ul of the target cell suspension.
In experiments designed to establish the role of effector-target 
cell-cell contact and to assess the possibility of nonspecific 
inhibition or stimulation of progenitor cell growth due to the 
presence of LAK cells or LAK-derived cytokines in the semi-solid 
culture medium, LAK cells at the same effector:target ratio were 
added to the progenitor cells immediately before plating. All LAK 
cells were irradiated (5 Gy) before use to prevent them from
• • 173 • • •forming colonies . CFU-GM colonies were defined as granulocytic, 
monocytic or mixed aggregates containing more than 2 0 cells. They 
were scored on day 14 under an inverted microscope. The number of 
colonies cultured from 105 normal marrow or CML mononuclear cells 
cultured in the absence of LAK cells was taken as 100%. In the 
cultures containing LAK cells the percentage of surviving 
progenitor cells was calculated by dividing the total number of
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colonies by the number of colonies obtained in cultures free of LAK 
cells x 100%.
STATISTICAL METHODS
Differences in colony numbers in the CFU-GM assay were assessed for 
significance using the paired two-tailed Student's t-test.
RESULTS
SURFACE MARKERS
The surface marker analysis of the LAK cells from both the donors 
and recipients is shown in Table 4. I generated both CD56+, CD16+, 
CD3- NK cells and CD3+, CD56-, CD16- cytotoxic T cells. Although 
the LAK cells obtained from the recipients appeared to contain more 
NK and fewer T cells than those of the donors, these differences 
were not statistically significant.
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TABLE 4
Phenotype of the LAK cells generated from donors and recipients 
expressed as mean percent values + one standard deviation.
Percent cells positive for
CD3 CD4 CD8 CD16 CD56
Recipients 
(n = 19)
45+25 11+13 48+19 7±5 53+25
Donors 57+7 24+8 34+8 10+7 39+10
(n = 6)
CFU-GM ASSAY
LAK cells were generated from PBMC of 24 transplant recipients. 
The effect of LAK cell derived diffusible factors in the CFU-GM 
cultures was evaluated by comparing cultures grown in the absence 
of LAK cells with those cultures in which the LAK cells were not 
in contact with the CML progenitors during the liquid phase. LAK 
cells significantly (p < 0.05) increased colony numbers in 8
assays, significantly (p < 0.05) decreased colony numbers in 10 
assays and made no difference in 6 assays in the absence of 
effector-target cell contact (Fig. 11).
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Figure 11. Activity of LAK cells generated from 24 transplant 
recipients using recipient CML cells as targets. Numbers of CFU- 
GM obtained in triplicate cultures are expressed as the mean 
percentage + one standard deviation of colony numbers obtained in 
cultures without LAK cells. Experiments marked "S" involved 
syngeneic transplants.
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To assess any influence of effector-target cell contact independent 
of the effects of LAK cell cytokine release I compared experiments 
in which LAK cells were or were not in cell-cell contact with the 
CML progenitors in liquid culture prior to plating in the 
methylcellulose. These two sets of data are presented with the 
results expressed as mean percentages of the colony numbers 
obtained in cultures without LAK cells. I found significant (p < 
0.05) inhibition of CFU-GM proliferation from CML cells in 18 (2 
syngeneic) of the 24 (75%) experiments (Fig. 11). The mean + SEM 
inhibition in these 18 studies was 47% + 5 (range, 19 - 87%). No 
significant difference was seen on 3 occasions and significant 
stimulation (p < 0.05) of colony growth in 3 assays (Fig. 11).
I then compared the activity of LAK cells cultured from 1 syngeneic 
and 5 HLA-identical sibling transplant recipients incubated 
simultaneously with either donor marrow progenitors or recipient 
CML progenitors. LAK cells inhibited CML CFU-GM proliferation to 
a significant degree in all 6 experiments (mean + SEM: 49% + 9, 
range 19 - 85%) (Fig 12A), whereas proliferation of donor marrow 
CFU-GM was significantly inhibited in only 2 of the 6 experiments 
(31 and 33%) (Fig. 12B) .
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Similarly, the activity of LAK cells generated from 1 syngeneic and 
7 sibling allogeneic bone marrow donors was assessed in analogous 
experiments. Of the 8 donors 7 were males or nulliparous females 
with no previous blood transfusions. Both donor marrow and 
recipient CML cells were used as concurrent targets. Donor LAK 
cells inhibited recipient leukaemia CFU-GM proliferation to a 
significant degree in 6 of 8 experiments (mean + SEM: 52% + 7,
range 38 - 86%) (Fig. 13A), whereas proliferation of donor marrow 
CFU-GM was significantly inhibited (36%) in only one experiment 
(Fig. 13B).
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DISCUSSION
This study demonstrates that LAK cells generated from either the 
bone marrow of the donor pretransplant or the recipient post-BMT 
inhibited the growth of recipient CML CFU-GM with sparing or 
relative sparing of donor marrow CFU-GM.
The effector cells responsible for this activity fell into two main 
populations: CD56+, CD16+, CD8dim+, CD3- NK cells and CD3+,
CD8bnght+, CD56-, CD16- T cells (Table 1) . Immune reconstitution 
following BMT results in replacement of the recipients' NK and T 
cells with those of donor origin119,134. Therefore because all the 
effectors used in this study were donor derived and the targets 
were either autologous (donor marrow) or allogeneic (HLA-identical 
recipient leukaemia), it might be argued that any antileukemic 
activity could be due to a combination of MHC unrestricted NK cells 
and an allogeneic component mediated by donor derived T cells which 
recognise minor transplantation antigens. However it seems 
probable that allogeneic factors are not important in this assay 
system for three reasons: 1) the two patients studied following 
syngeneic BMT both showed inhibition of colony growth of the 
leukaemic marrow, 2) previous in vitro studies performed using a 
cytotoxic assay demonstrated that T cells were not important in 
mediating this in vitro GVL effect arid that the LAK activity was 
present in the CD564-, CD16+, CD8dim+, CD3- activated NK cells, and 
3) effector cells generated from the male or female nulliparous
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untransfused HLA identical sibling donors prior to the transplant 
could not have been primed to respond to any minor HLA antigen 
differences between donor and recipient. Furthermore in HLA- 
identical siblings the cytotoxic T lymphocyte precursor frequency 
in the graft-versus-host direction is extremely low, i.e. between 
1 in 300,000 and < 1 in 1,000,000 making a specific allogeneic T
17L.cell cytotoxic effect unlikely
The experiments demonstrated stimulation as well as inhibition of 
colony growth when LAK cells were added to the cultures immediately 
before plating in methylcellulose but not in cell-cell contact with 
the progenitor cells (Fig. 11) . These effects were mediated by 
LAK-derived diffusible factors which we presume to be the cytokines 
reported by a number of investigators109,166'168,170'175. These apparently 
contradictory findings can be explained by the fact that LAK cells 
produce colony stimulating factors whose growth promoting 
activities may be masked by colony inhibiting activity due to
170 •concurrent release of TNF . Therefore by assessing the net 
inhibition or stimulation of LAK cytokine release on the individual 
cultures, it was possible to define the role of LAK-target cell 
contact.
The experiments performed with pre-incubation of LAK cells and 
target cells together in liquid culture allowed me to determine the 
consequences of this cell-cell contact. Although significant 
inhibition of colony growth was seen in the majority of the
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recipients' CML progenitors (Figs. 11, 12A and 13A), there was a 
similar effect in only a minority of cultures where normal donor 
marrow was the target, and then in an attenuated form (Figs. 12B 
and 13B). The mechanisms underlying this antileukemic activity 
with complete or relative sparing of normal marrow remain poorly 
characterized. Possible mechanisms include enhanced LAK cell 
recognition of leukaemic targets with resultant triggering of the 
perforin107 mediated lysis or local release of cytokines such as 
TNF or gamma interferon which are known to affect leukaemic cells 
more than normal cells176’178. The studies in Chapter 3 using a 51Cr 
release cytotoxicity assay demonstrated that the LAK cells are 
capable of lysing CML targets, suggesting that the reduction in 
colony numbers seen may be a reflection of progenitor cell death 
rather than merely an inhibition of cell division.
In conclusion, LAK cells may inhibit the growth of normal bone 
marrow cells to some extent but the in vitro data presented here 
indicate that the susceptibility of donor marrow is still 
considerably less than that of recipient CML progenitors. This 
might allow IL-2/LAK cell therapy following BMT to enhance 
antileukemic activity without compromising engraftment. In the 
context of syngeneic or autologous BMT, this GVL activity could be 
generated without the risk of initiating or enhancing GVHD. In 
allogeneic BMT, however, the use of IL-2/LAK cell therapy in vivo 
could promote the growth of donor alloreactive T cells with 
resultant GVHD. Animal data suggest that this might be avoided if
one could deplete the donor marrow of T cells prior to the 
transplant160. Whether this in vitro GVL activity can be exploited 
in the clinic is at present unclear but preliminary studies in 
which patients received IL-2 post-autografting indicate that LAK 
cell activity is indeed enhanced136.
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CHAPTER 5
ORIGIN AND FUNCTION OF ADHERENT LYMPHOKINE ACTIVATED KILLER 
CELLS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA WHO 
RELAPSE FOLLOWING BONE MARROW TRANSPLANTATION
94
INTRODUCTION
The probability of relapse at 4 years is about 10% following 
allogeneic BMT for CML using unmanipulated donor marrow but GVHD
• • 125 •remains a major complication . T cell depletion of the donor 
marrow reduces the incidence and severity of GVHD but increases 
the probability of relapse to 50% or higher37. This observation 
provides support for the existence of a GVL effect in CML.
Some of the CML patients who relapse following BMT have "low grade" 
disease which is often asymptomatic without splenomegaly and
• • • 179requiring little or no treatment . It could be argued that the 
apparent slow progression of disease reflects a reduced total 
myeloid cell mass at the time of detection of relapse after BMT and 
not an alteration in biological tempo. However in the majority of 
cases of newly diagnosed CML evidence of leukaemia is probably only 
present in the peripheral blood for 6 - 1 2  months prior to actual 
diagnosis180. Thus it is possible that even in patients who relapse 
post-BMT, leukaemic cell proliferation could still be restrained 
to some extent by a GVL effect mediated by lymphoid cells of donor 
origin.
A method has recently been developed for selective enrichment of 
recombinant IL-2 activated antitumour effector cells called
adherent lymphokine activated killer (ALAK) cells from rat
181 • 182 splenocytes or from human peripheral blood mononuclear cells
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The method depends on the propensity of activated NK cells to
adhere tightly to plastic in the presence of IL-2. Cultivation of
these adherent cells with IL-2 for 14 days results in the rapid
proliferation of cells with the morphological characteristics of
large granular lymphocytes and a predominant CD56+/CD3- phenotype.
ALAK cells derived from normal humans have significantly higher
cytotoxic activity on a per cell basis and greater proliferative
181 182capacity than LAK cells prepared m  a conventional fashion '
The ALAK population has not been studied in patients who have 
relapsed after BMT for CML. I wanted to determine whether these 
cells were of donor or recipient origin. I also wanted to assess 
their phenotype and whether the ALAK cells were capable of in vitro 
antileukaemia or GVL activity. If ALAK cells were capable of 
mediating an in vitro GVL effect this might support the hypothesis 
that the donor lymphoid cells inhibited leukaemic cell 
proliferation after transplant and this resulted in "low grade" 
chronic phase disease.
96
MATERIALS AND METHODS
PATIENTS
I studied in 7 patients following T cell depleted BMT for CML. 
Five patients were in haematological relapse, one was in 
cytogenetic relapse and the other patient was in complete 
cytogenetic remission at the time of study but had prior 
documentation of cytogenetic relapse. Four patients had received 
allogeneic marrow from HLA identical siblings, 2 received marrow 
from HLA matched unrelated donors and one patient received marrow 
from a one antigen mismatched family member. Pretransplant all 
patients were conditioned with cyclophosphamide (60 mg/kg/day x 2) 
and total body irradiation (6x2 Gy). Some patients also received 
additional chemotherapy, total lymphoid irradiation or splenic 
irradiation. Patients were studied at intervals ranging from 1 to 
4 years following BMT.
GENERATION OF ALAK CELLS
Venous blood was collected from the patients following the 
transplant and PBMC were prepared by centrifugation on Lymphoprep 
(Nyegaard, Oslo). The low density cells were collected and washed 
twice with HBSS and resuspended in RPMI-AB and depleted of 
monocytes by plastic adherence.
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For generation of ALAK cells, monocyte depleted PBMC at a 
concentration of 4 x 106/imL were incubated in a plastic culture 
flask (Falcon, Lincoln Park, NJ) for 24 hours in 5% C02 at 37°C in 
RPMI-AB containing 500 U/ml recombinant IL-2. After incubation the 
supernatant was decanted and all cells not firmly attached to
plastic were removed by washing x3 with HBSS at 37 °C. In
• • 181 182 distinction to the original method ' the adherent cells were then
refed with fresh RPMI-AB supplemented with 500 U/ml IL-2 rather
than with autologous conditioned media and cultured for up to 14 
111days . The ALAK cells were washed and then tested for phenotype 
and antileukaemic activity. Metaphases were prepared for 
cytogenetic studies (see below).
SURFACE MARKER ANALYSIS
Phenotypic analysis was performed by two-colour direct
• • • 152 • •immunofluorescence using standard techniques as described m  
Chapter 3.
ELIMINATION OF T LYMPHOCYTE SUBPOPULATIONS
T cell depletion of the ALAK cells was performed by the method 
described in Chapter 3.
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ANTILEUKAEMIC ACTIVITY OF THE ALAK CELLS
ALAK cells were tested for activity using the 51Cr release cytotoxic 
assay described in Chapter 2.
CYTOGENETIC ANALYSIS
T cell depleted ALAK cells were resuspended in RPMI-AB supplemented 
with 500 U/ml IL-2 and cultures harvested for cytogenetic analysis 
after 24 hours. Colcemid (Gibco, Paisley, Scotland) was added to 
the cultures at a final concentration of 0.1 ug/ml which were then 
left for 60 minutes at 37°C before harvesting. Thereafter the 
cells were centrifuged at 1000 rpm for 8 minutes. The supernatant 
was removed and the cell pellet was resuspended in 2 ml of 0.075 
M hypotonic KC1 and left at 37°C for 3 - 5  minutes. Cells were 
then centrifuged at 1000 rpm for 8 minutes and the supernatant 
removed. The resuspended cells were then fixed in freshly made 3:1 
methanol:acetic acid solution. The fixed cells were left at -20°C 
overnight. They were then centrifuged and the supernatant removed. 
The pellet was then resuspended in fresh fix solution to a suitable 
dilution for slide making. Metaphase spreads were made as follows. 
The cell suspension was dropped onto a microscope slide and left 
on a 60°C hot plate for 1 hour. Metaphases were banded using a 
Trypsin-Giemsa method adapted from Seabright183. Between 9 - 41 
metaphases were analyzed for each patient.
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RESULTS
SURFACE MARKERS
Phenotypic analysis of cells from the 7 patients at day 14 of ALAK 
culture revealed that 49 + 6% were CD56+/CD3-, 50 + 11% were
CD3+/CD56- with a few CD3+/CD56+ cells being found (5 + 2%). The 
CD56+ cells were either CD16- (40 + 6%) or CD16dim (9 + 6%) . Figure 
14 which is a two-colour FACS analysis of ALAK cells from a single 
patient demonstrating that the CD3 and CD56 antigens were largely 
present on two different populations of cells.
CHROMOSOME ANALYSIS
Cytogenetic analysis of T cell depleted ALAK metaphases from the 
7 patients are shown in Table 5. The patients' leukaemia 
transplant number (LTN), disease status, recipient/donor sex and 
number of metaphases studied are detailed. The ALAK cells from 6 
patients were all Ph negative, and where donor and recipient were 
sex mismatched, ALAK cells were exclusively of donor origin. In 
patient LTN 102 the ALAK cells were of recipient origin in 8 of 9 
metaphases. In addition all recipient cells had the Ph chromosome. 
The phenotype of the T cell depleted ALAK cells from patient LTN 
102 are shown in Figure 15 and indicated that >97% of the cells 
were CD56+/CD3- activated NK cells. In patient LTN 135, where 
donor and recipient were both female, we were able to determine
whether the ALAK cells were of donor or recipient origin. By 
analyzing phytohaemagglutinin stimulated T cells from this patient 
post-BMT we were able to identify two populations of cells (donor 
and recipient) on the basis of chromosome 15 satellite 
polymorphisms (Fig. 16) . The ALAK cells were all of recipient 
origin but lacked the Ph chromosome unlike the recipient myeloid 
cells which were Ph positive.
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Figure 14. Two colour flow cytometric analysis of day 14 ALAK 
cells from a single patient. Histogram showing: FL1 FITC anti-CD3; 
FL2 PE anti-CD56. The CD3+ T-cells and CD56+ cells are largely 
separate populations with only a few T cells expressing both 
antigens.
Figure 15. Two colour flow cytometric analysis of day 14 T cell 
depleted ALAK cells from a patient LTN 102. Histogram showing: FL1 
FITC anti-CD3? FL2 PE anti-CD56. The figure shows that >97% of the 
cells are CD56+/CD3- activated NK cells.
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ANTILEUKAEMIC ACTIVITY OF ALAK CELLS
T cell depleted ALAK cells significantly killed recipient CML cells 
in 5 of 7 patients studied (Fig. 17) with a mean + SEM specific 
lysis of 28% + 5 at an E:T ratio of 50:1. The recipient-derived 
Ph positive ALAK cells from patient LTN 102 were CML lytic. The 
ALAK cells from 2 patients (LTNs 83 and 135) did not kill their 
pretransplant CML cells.
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Figure 17. Results from the 5 patients whose T-depleted ALAK cells 
demonstrated significant lysis of the CML targets. ALAK cells were 
added to recipient CML cells at E:T ratios of 50, 25, 12, 6 and 3 
to 1. Each E:T ratio was set up in triplicate and the points 
plotted are the mean 51Cr release. The graph shows dose-dependent 
killing of the CML targets.
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DISCUSSION
The phenotype of the ALAK cells generated from CML patients in 
relapse after BMT was different from that reported in previous
studies on both normal subjects and in chronic phase CML patients
111 182 • •who have not been transplanted ' . Although we had a majority
population of CD56+, CD3- activated NK cells as reported by others,
we generated more CD3+ T cells. The reason for this difference is
unclear but it could reflect disordered immune reconstitution
following the transplant. One consequence of these findings was
that we decided to T cell deplete the ALAK cells before performing
cytogenetic analysis and testing for antileukaemic activity.
The ALAK cells were able to lyse recipient CML cells in 5 of the 
7 patients. These results are similar to those seen in Chapter 3 
using LAK cells from transplant patients in remission of disease. 
Somewhat surprisingly even the recipient Ph positive ALAK cells 
lysed the recipient CML cells. Thus in patients in haematological 
relapse post-BMT there remains a population of cells capable of 
being stimulated to produce an in vitro antileukaemic or GVL 
effect. Therefore it is possible that even in patients who relapse 
after T cell depleted BMT leukaemic cell proliferation may be 
restrained to some extent by a GVL effect mediated by lymphocytes 
of donor origin. The observation that cytogenetic relapse may on
/  c <i o /
occasion be transient ' or may persist without progression to 
haematological relapse30 has been reported previously and provides
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further support for this hypothesis.
In 2 patients the ALAK cells were of recipient origin and in one 
of these the ALAK cells were Ph positive and therefore part of the 
malignant clone, a finding not previously reported either before 
or following BMT. These results were obtained from a population 
of cells >97% CD56+, CD3-. NK cells were reported to be of donor
4 7 7
origin in transplant recipients in remission ' . Our results
demonstrate that in all other patients studied the ALAK cells were 
Ph negative, and when the donor and recipient were sex mismatched, 
the ALAK cells were exclusively of donor origin. When T cells and 
B cells were studied in relapsed patients transplanted for CML or 
acute leukaemia similar findings were documented with those 
lymphocytes also being of donor origin179,185.
In practice most of the patients studied progressed to 
haematological relapse in vivo even though some possessed donor NK 
cells capable of being stimulated to produce an in vitro GVL 
effect. CML transplant recipients are particularly prone to 
relapse when they receive a donor marrow depleted of T cells with 
a monoclonal antibody of broad specificity such as Campath-135. 
Immune reconstitution in such patients is associated with a rapid 
recovery of NK cells but with a marked delay in the reappearance 
of the CD4+ helper T-cells126 responsible for the production of IL- 
2 in vivo. Although donor NK cells activated in vitro can mediate 
GVL activity it is possible that a failure of the helper T cells
to fully activate the NK cells in vivo following T cell depleted 
BMT results in a loss of GVL activity resulting in an increase in 
leukaemic relapse. If such a mechanism was deficient in T cell 
depleted BMT recipients, the in vivo administration of IL-2 post- 
BMT might enhance GVL activity and reduce leukaemic relapse. 
Although this might be associated with augmentation of GVHD, murine 
studies indicate that this might not be a problem in the context 
of a T-cell depleted donor marrow160.
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CONCLUSIONS
The data presented in this thesis have demonstrated that it is 
possible to induce in vitro GVL activity following BMT for CML. 
This activity is MHC unrestricted and mediated by activated NK 
cells. The LAK cells not only lysed the CML cells but also 
prevented their proliferation. The growth of normal donor marrow 
CFU-GM was either not affected or inhibited to a lesser extent than 
that of the CML progenitors. In similar experiments in patients 
who had relapsed post-BMT the ALAK population was usually of donor 
origin and capable of mediating in vitro GVL activity.
It is tempting to speculate that this inducible in vitro GVL 
activity might have an in vivo counterpart, and that loss of in 
vivo NK activity following lymphocyte depletion of the donor marrow 
is responsible for the increased incidence of relapse. One can 
develop theories in which a number of separate small changes 
associated with lymphocyte depletion could lead to a large increase 
in post-BMT leukaemic relapse. Removal of NK cells as well as T 
cells from the donor marrow, impaired reconstitution of the IL-2 
producing helper T cells and minimal residual CML leukaemia cells 
which release soluble IL-2R could all be factors which might act 
synergistically to increase relapse. However, apart from the 
results of the syngeneic transplants, which have a lower relapse 
rate than T cell depleted allografts for CML35, there is scant 
evidence to support the concept of in vivo GVL mediated by NK
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cells. In vivo the majority of the GVL effect is related to 
concurrent GVHD mediated by T cells. Furthermore the data 
presented in this thesis failed to show a correlation between 
induction of in vitro NK cell mediated GVL activity and the 
patients' clinical transplant parameters.
Although it might be construed as disappointing that the inducible 
in vitro GVL effect bears little relationship to what is happening 
in vivo, one need not view the results in that manner. There would 
have been little gained by reproducing the in vivo GVL effect with 
IL-2 in vitro as this would have been largely a T cell mediated 
effect and would therefore almost certainly result in an increase 
in GVHD with its associated morbidity and mortality when
transferred to the clinic. By producing in vitro GVL activity 
mediated by activated NK cells, GVHD might be avoided after 
allogeneic BMT. There are murine data to support the view that IL- 
2 therapy post allogeneic BMT might not be associated with GVHD 
when the donor marrow is T cell depleted. However mice are not men 
and until the results of ongoing primate transplantation studies 
are available, it will not be ethical to use post-BMT IL-2/LAK 
therapy following allografting. However the results of the
syngeneic studies presented in this thesis indicate that IL-2/LAK 
therapy post-autografting might reduce leukaemic relapse without 
any risk of GVHD. Preliminary studies have shown that post
autologous BMT IL-2 infusion does enhance in vivo LAK activity but
it is currently too early to determine whether this will result in
Ill
a reduction in leukaemia relapse.
Leukaemia patients in the early phase post-BMT could be seen as the 
ideal candidates for adoptive immunotherapy. The combination of 
a non-solid malignancy, minimal tumour load post-BMT, easy 
targeting of leukaemic cells either in the blood or bone marrow 
together with an already enhanced NK activity post-BMT should 
provide the ideal environment for in vivo IL-2/LAK therapy. 
Whether recombinant cytokines either alone or in combination will 
result in improved clinical results of BMT is currently not known 
but this question will only be answered by randomized prospective 
clinical trials.
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